Bedaquiline + Pretomanid + Linezolid
This drug combination represents the first TB regimen with no pre-existing resistance to reach testing in humans. It was identified by its impressive performance in vitro in TB Alliance’s preclinical regimen identification program. This regimen has the potential to shorten TB treatment to less than 4 months for patients sensitive to the therapies in the regimen, including some MDR-TB patients. This is an oral regimen, removing the need for injectables as part of MDR-TB treatment and also projecting to be markedly less expensive than current MDR-TB therapy. This regimen also shows promise to be able to be administered alongside common ARV treatments, thereby improving treatment options for patients co-infected with TB and HIV. Additionally, this regimen can be administered in a fixed dose for all patients, and will therefore be simpler for health systems to deliver and patients to use.